{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:37:55Z","timestamp":1790613475817,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["F30 HD097925"],"award-info":[{"award-number":["F30 HD097925"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD096737"],"award-info":[{"award-number":["R01 HD096737"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jbc.2022.101646","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T05:30:59Z","timestamp":1643347859000},"page":"101646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacological chaperones for the oxytocin receptor increase oxytocin responsiveness in myometrial cells"],"prefix":"10.1016","volume":"298","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4203-962X","authenticated-orcid":false,"given":"Manasi","family":"Malik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingye","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monali","family":"Wakle-Prabagaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Prifti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina I.","family":"Frolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princess I.","family":"Imoukhuede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-0281","authenticated-orcid":false,"given":"Sarah K.","family":"England","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2022.101646_bib1","first-page":"1","article-title":"Births: Final data for 2019","volume":"70","author":"Martin","year":"2021","journal-title":"Natl. Vital Stat. Rep."},{"key":"10.1016\/j.jbc.2022.101646_bib2","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1097\/AOG.0000000000002351","article-title":"Practice bulletin no. 183: Postpartum hemorrhage","volume":"130","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jbc.2022.101646_bib3","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3109\/14767058.2014.963046","article-title":"Factors associated with higher oxytocin requirements in labor","volume":"28","author":"Frey","year":"2015","journal-title":"J.\u00a0Matern. Fetal Neonatal. Med."},{"key":"10.1016\/j.jbc.2022.101646_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/AOG.0b013e3182854b36","article-title":"Preventing the first cesarean delivery: Summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists workshop. In reply","volume":"121","author":"Spong","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jbc.2022.101646_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejogrb.2020.06.018","article-title":"Maternal and neonatal outcomes following a prolonged second stage of labor: A meta-analysis of observational studies","volume":"252","author":"Pergialiotis","year":"2020","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jbc.2022.101646_bib6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/14767058.2013.818970","article-title":"Peripartum complications with cesarean delivery: A review of maternal-fetal medicine units network publications","volume":"27","author":"Hammad","year":"2014","journal-title":"J.\u00a0Matern. Fetal Neonatal. Med."},{"key":"10.1016\/j.jbc.2022.101646_bib7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJM197508282930902","article-title":"Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy","volume":"293","author":"Miller","year":"1975","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jbc.2022.101646_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.116.232884","article-title":"Comparison of the beta-adrenergic receptor antagonists landiolol and esmolol: Receptor selectivity, partial agonism, and pharmacochaperoning actions","volume":"359","author":"Nasrollahi-Shirazi","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jbc.2022.101646_bib9","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1210\/er.2013-1121","article-title":"Chaperoning G protein-coupled receptors: From cell biology to therapeutics","volume":"35","author":"Tao","year":"2014","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jbc.2022.101646_bib10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1172\/JCI8688","article-title":"Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants","volume":"105","author":"Morello","year":"2000","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jbc.2022.101646_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1152\/physrev.2001.81.2.629","article-title":"The oxytocin receptor system: Structure, function, and regulation","volume":"81","author":"Gimpl","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jbc.2022.101646_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/er.2012-1044","article-title":"Nephrogenic diabetes insipidus: Essential insights into the molecular background and potential therapies for treatment","volume":"34","author":"Moeller","year":"2013","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jbc.2022.101646_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2005080854","article-title":"Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus","volume":"17","author":"Bernier","year":"2006","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.jbc.2022.101646_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2017_50","article-title":"Pharmacological chaperones as potential therapeutic strategies for misfolded mutant vasopressin receptors","volume":"245","author":"Mouillac","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jbc.2022.101646_bib15","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ejhg.2017.130","article-title":"SweGen: A whole-genome data resource of genetic variability in a cross-section of the Swedish population","volume":"25","author":"Ameur","year":"2017","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.jbc.2022.101646_bib16","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/acsptsci.1c00095","article-title":"Naturally occurring genetic variants in the oxytocin receptor alter receptor signaling profiles","volume":"4","author":"Malik","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jbc.2022.101646_bib17","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/acs.jpcb.7b02914","article-title":"Predicting a drug's membrane permeability: A computational model validated with in\u00a0vitro permeability assay data","volume":"121","author":"Bennion","year":"2017","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.jbc.2022.101646_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1021\/jm049661n","article-title":"In silico prediction of membrane permeability from calculated molecular parameters","volume":"48","author":"Refsgaard","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2022.101646_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-4939-6840-4_8","article-title":"qFlow cytometry-based receptoromic screening: A high-throughput quantification approach informing biomarker selection and nanosensor development","volume":"1570","author":"Chen","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jbc.2022.101646_bib20","doi-asserted-by":"crossref","first-page":"19452","DOI":"10.1074\/jbc.M101450200","article-title":"Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis\u2217","volume":"276","author":"Oakley","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2022.101646_bib21","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1210\/me.2003-0440","article-title":"Real-time detection of interactions between the human oxytocin receptor and G protein-coupled receptor kinase-2","volume":"18","author":"Hasbi","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jbc.2022.101646_bib22","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1111\/bph.12699","article-title":"Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325","volume":"171","author":"Iijima","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jbc.2022.101646_bib23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1095\/biolreprod67.2.506","article-title":"Telomerase immortalization of human myometrial cells","volume":"67","author":"Condon","year":"2002","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.jbc.2022.101646_bib24","doi-asserted-by":"crossref","first-page":"47254","DOI":"10.1074\/jbc.M408154200","article-title":"Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors","volume":"279","author":"Wuller","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2022.101646_bib25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.coph.2004.08.001","article-title":"Pharmacological chaperone action on G-protein-coupled receptors","volume":"4","author":"Bernier","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jbc.2022.101646_bib26","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/me.2004-0080","article-title":"Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059","volume":"18","author":"Bernier","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jbc.2022.101646_bib27","doi-asserted-by":"crossref","first-page":"F253","DOI":"10.1152\/ajprenal.00247.2006","article-title":"Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: Relevance to therapy of nephrogenic diabetes insipidus","volume":"292","author":"Robben","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.jbc.2022.101646_bib28","article-title":"Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes","author":"Karczewski","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.jbc.2022.101646_bib29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2818.2006.01706.x","article-title":"A\u00a0guided tour into subcellular colocalization analysis in light microscopy","volume":"224","author":"Bolte","year":"2006","journal-title":"J.\u00a0Microsc."},{"key":"10.1016\/j.jbc.2022.101646_bib30","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1476-5381.2010.00879.x","article-title":"Matching models to data: A receptor pharmacologist's guide","volume":"161","author":"Hall","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jbc.2022.101646_bib31","first-page":"G982","article-title":"Analysis and comparison of sigmoidal curves: Application to dose-response data","volume":"257","author":"Meddings","year":"1989","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.jbc.2022.101646_bib32","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/jm901084f","article-title":"Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist","volume":"53","author":"Frantz","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2022.101646_bib33","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0968-0896(99)00101-7","article-title":"7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist","volume":"7","author":"Kondo","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jbc.2022.101646_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2009.07.016","article-title":"Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist","volume":"58","author":"Ring","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jbc.2022.101646_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3565(24)36784-9","article-title":"Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in\u00a0vitro and in\u00a0vivo","volume":"282","author":"Tahara","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jbc.2022.101646_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.bjp.0702996","article-title":"Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells","volume":"129","author":"Tahara","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jbc.2022.101646_bib37","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/sj.bjp.0706383","article-title":"Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: Evidence that SSR149415 is a mixed vasopressin V1b\/oxytocin receptor antagonist","volume":"146","author":"Griffante","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jbc.2022.101646_bib38","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1021\/jm00023a002","article-title":"1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): A new, orally bioavailable, non-peptide oxytocin antagonist","volume":"38","author":"Williams","year":"1995","journal-title":"J.\u00a0Med. Chem."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925822000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925822000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:16:33Z","timestamp":1758240993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925822000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0021925822000862"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2022.101646","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741604212.793592531","asserted-by":"object"}]},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological chaperones for the oxytocin receptor increase oxytocin responsiveness in myometrial cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2022.101646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101646"}}